for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Stealth BioTherapeutics' neuromuscular disorder drug fails late-stage study

Dec 20 (Reuters) - Stealth BioTherapeutics Corp said on Friday its drug to treat neuromuscular diseases failed to meet the main goals of a late-stage trial.

The trial was testing the drug, elamipretide, to treat patients with primary mitochondrial myopathy, but failed to help patients walk better and reduce fatigue, the company said. (reut.rs/3918ob9) (Reporting by Trisha Roy in Bengaluru; Editing by Shounak Dasgupta)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up